Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Beta Drugs Limited reported strong consolidated FY25 results with total revenue rising 24.1% to Rs 368.8 crore from Rs 297.1 crore in FY24, driven by 25.3% growth in Own Brands and 72.7% growth in exports. Consolidated EBITDA stood at Rs 81.04 crore with margins of 22.37%, while net profit before exceptional items grew 25.8% to Rs 45.83 crore. After accounting for one-time exceptional expenses of Rs 4.57 crore (related to a Nov 2024 preferential issue), reported net profit came in at Rs 42.41 crore with an 11.7% net margin. The company remains net debt-free, with cash and equivalents exceeding borrowings by Rs 14.32 crore. The statutory auditor (Khurana Sharma & Co.) issued an unmodified (clean) opinion on both standalone and consolidated results. Standalone results were weaker, with PAT of Rs 15.43 crore vs Rs 21.94 crore in FY24.
Strong topline growth, healthy margins, and net debt-free status are positives, while the standalone PAT decline and the drag from preferential issue expenses are minor concerns. Management's FY26 guidance of Rs 450+ crore revenue and 23-24% EBITDA margins signals continued momentum, which is supportive of the stock.